Clinical trial NCT03845907: Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Official title: Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: NA
Conditions: Breast Cancer
Lead sponsor: Seno Medical Instruments Inc.
Sponsor class: INDUSTRY
First posted: 2019-02-19
Enrollment: 4
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Unblinded feasibility study in healthy subjects
Primary purpose: OTHER

Brief summary: Comparative Evaluation of Gen1B (OA-16-1S) duplex OA/US probe versus Gen1 (OA-16-1) duplex OA/US probe in Healthy Subjects

Detailed description: This study performs the first clinical evaluation of the Gen1B (OA-16-1S) duplex OA/US probe. This probe includes design changes to improve reliability and performance compared to the Gen1 (OA-16-1) duplex OA/US probe. The performance of the Gen1 duplex probe is functionally equivalent to the PIONEER duplex probe (OA-15-3), which was used in previous clinical studies for suspicious breast masses.

Eligibility criteria: Inclusion Criteria:

* Has a signed and dated informed consent, prior to initiation of any study-related activities.
* Is at least 18 years of age.
* Is willing to undergo an Imagio imaging evaluation and standard Ultrasound Evaluation of the breast and axillary lymph nodes.
* Is willing and able to comply with protocol-required scans.

Exclusion Criteria:

* Is pregnant or lactating.
* Has a condition or impediment (i.e. insect bites, poison ivy, rash, open wounds, chafing of the skin, scar, tattoos, moles, breast implants within the previous 12 months, etc.) where the duplex probe will come in contact with the subject, which could interfere with the intended field of view.
* Is experiencing photo-toxicity associated with currently taking, or having taken, photosensitizing agents within the previous 72 hours such as sulfa, ampicillin, tetracycline.
* Is currently undergoing phototherapy.
* Has a history of any photosensitive disease (e.g., porphyria, lupus erythematosus) or undergoing treatment for a photosensitive disease and is experiencing photosensitivity.
* Has had an adverse reaction in the past to medical laser procedures, such as laser hair removal or laser tattoo removal.
* Has had a history of contact dermatitis induced by gold or chrome metal contact with skin.
* Has an acute or chronic hematoma and/or acute ecchymosis of the breast.
* Has had prior benign excisional breast biopsy within the past 18 months.
* Has nipple rings that cannot be removed or are not removed during Imagio evaluation.
* Currently has mastitis.
* Has focal pain in the breast.

Primary outcomes:
measure: Number of Subjects with Treatment-related Events
timeFrame: At end of study, average of six months
measure: Diagnostic Image Quality of Gen 1B
timeFrame: At end of study, average of six months
Secondary outcomes:
measure: Probe performance data comparison across skin types
timeFrame: At end of study, average of six months
measure: Image Quality between probes at reduced laser level
timeFrame: At end of study, average of six months
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: Seno Medical
state: Texas
Study officials:
affiliation: Seno Medical
name: A. Thomas Stavros, MD
role: STUDY_DIRECTOR
References: